chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left arm soreness for 24 hours and low grade fever of 100 F; Left arm soreness for 24 hours and low grade fever of 100 F; This is a spontaneous report from a contactable nurse. A 53-year-old non-pregnant female received bnt162b2 (lot: EK9231), intramuscular in the left arm on 30Dec2020 14:30 at a single dose for covid-19 immunization. The patient's medical history included migraine, seizure (resolved x2years) from an unknown date and unknown if ongoing , and allergy to penicillin. There were no concomitant medications. On 30Dec2020 20:00, the patient experienced left arm soreness for 24 hours and low grade fever of 100 f. The outcome of the event was recovered on an unknown date. No treatment was given to the patient for the event. The vaccine was administered in a hospital. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient did not have Covid prior to vaccination and has not been tested post vaccination.
devel red raised rash under arms & on back 30JUL; pt put on hydrocoritzone cream; rash spread to legs, chest & abd; DPH & aloe w/lidociaine to rash; 31JUL rash returned; same tx; MD felt rxn to Td; next time pt should only have Tetanus;
Initial symptoms in the first 24 hours matched with prior exposures to the vaccine. Significant arm swelling, a small rash, and muscle aches. The trend changed after 24 hours. In prior exposures, influenza-like/COVID-19-like symptoms lasted for up to 12 days. In this exposure, none of these symptoms was present. Instead, muscle aches worsened significantly, Vitamin D levels dropped to dangerously low levels, heart rate became increased, and chest pain was present upon exerted movements such as getting out of a chair. The chest pain resolved after 4-5 days but breathless has remained to the present day that impacts day to day exertions.
Developed  a 2cm in size swollen, tender, rubbery and mobile left supraclavicular lymphadenopathy 2 days post Pfizer vaccination. The node is still palpable but no longer tender or swollen and much smaller in size.
flu; Initial information received on 01-Dec-2022 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-healthcare professional.  This case involves a patient of unknown age and demographics who experienced flu after receiving vaccine influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect influenza vaccine produced by unknown manufacturer (strength, dose, formulation, frequency, lot number and expiry date: not reported) via unknown route in unknown administration site as prophylactic vaccination (Immunisation).  On an unknown date, the patient developed a non-serious event of flu (influenza) (unknown latency) following the administration of influenza vaccine.  No lab data was reported.  Action taken: Not applicable.  It was not reported if the patient received a corrective treatment for the event (flu).  At time of reporting, the outcome was Unknown for the event flu.
This case was reported by a healthcare professional and described the occurrence of red spot at injection site in a 5-year-old female subject who was vaccinated with KINRIX, GlaxoSmithKline. Previous and/or concurrent vaccination included MMR vaccine (non-GSK) (Merck; unknown; left arm given on 9 April 2010; varicella virus vaccine (non-GSK); Merck; unknown; right arm given on 9 April 2010. Concurrent medications included Multivitamin + fluoride. On 9 April 2010 at 15:30 the subject received 5th dose of KINRIX (unknown, right arm). On 12 April 2010, 3 days after vaccination with KINRIX, the subject experienced red spot at injection site. According to the mother, the redness was not there on the night of 11 April 2010 when the subject went to bed, but was there when she woke up on 12 April 2010. The red spot at injection site was described as three inches in diameter red spot around the injection site. At the time of reporting the red spot at injection site was unresolved. Follow-up information received on 07 May 2010 confirmed onset of the event to be 12 April 2010 with resolution on an unspecified date. It was corrected that VARIVAX was given in the right arm rather than the left as originally reported.
No other adverse effects were reported; a patient received a partial dose of Proquad because the patient moved his arm during administration of the vaccine; a patient received a partial dose of Proquad because the patient moved his arm during administration of the vaccine; This spontaneous report was received from a nurse and refers to a male patient of unknown age. No information regarding the patient's medical history, concurrent conditions, concomitant medications and previous drug reactions or allergies was reported.  On 22-JUN-2020, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis. The vaccine was reconstituted with a sterile diluent (STERILE DILUENT) 0.5 ml, injection.   The patient received a partial dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), because he moved his arm during the administration. The patient did not experience any additional adverse events.
Patient received vaccine then left the immunization booth.  Pharmacist was disinfecting the booth and heard the patient's mother saying   Pharmacist stepped out of the booth and the patient was on the floor.  Pharmacist went to the patient and instructed the staff to call 911.  Patient's mother (who is a RN) stated that the patient fainted and had a seizure.  Patient's mother stated the patient had a history of seizures (although on the consent form they marked no history).  Patient was conscious and had a pulse, she could talk - but she was very slow and labored in speech.  After a few minutes patient regained color in her face and was able to speak "normally".  At that time the patient stated that she had a history of seizures and that her last seizure was 2 years ago.  Patient also stated that her seizure triggers were fear and pain and that after the first shot she did experience dizziness (but had not told anyone about that).  Pharmacist stayed with the patient until EMS arrived, EMS took over care and took the patient to a local hospital for evaluation.
Lymph node swelling day after followed by diarrhea for a few days. Starting about 8 days after chills, headaches, fatigue, nasal congestion, sore throat and still having lymph node swelling.
Extreme muscle aches and tightening - neck, shoulders, chest.  Can barely move neck
Developed fever of 99.5 F following MMR vaccine. Fever was first noted 7 hours following vaccine administration.
On 2/13/06 received DTaP vac. On 2/14/06 at site of the injection has developed a large red welt aporx. 4"x5". Developed a fever and vomiting. Also my son has same symptoms both got vac. same day. Doctor has prescribe antibiotics and anti-inflammatory med.
Pt received intradermal flu shot at approx. 12:43pm soon after she felt lightheaded and almost fainted. Mom was with patient. We got her to sit down, gave her some water she started to feel better. Staff called ambulance as a precaution. Mom stayed w/daughter for about 10 min & stated her daughter was fine & refused ambulance she will follow-up w/MD if any other reactions are to occur.
House manager noticed 4 raised red bumps (hives) on left forearm. Pt was treated with Benadryl po given every 4 hours through the night.
Left ,shot injection site, thigh abscess - 1cm, drained and given BACTROBAN TID x 7.
Administered Pfizer 6mos-4yo monovalent dose when Pfizer 6mos-4yo bivalent dose was indicated.
Extreme chills and uncontrollable shaking. Severe headache. Slight fever. Coughing. Fatigue. Diarrhea. Body aches.
Sudden spike in frequency and intensity of symptoms appearing to be related to my pre-existing eosinophilic esophagitis and premature ventricular contractions; specifically, coughing triggered by irritated esophagus and feelings of becoming flushed and slightly faint from premature ventricular contraction).
I had a severe rash break out all around my neck, throat face arms and legs. My lips swelled up and felt tingly, and I had a severe headache.
This initial non-serious spontaneous case, was initially received from a physician on 13-Jul-2017 and concerns a patient  of unspecified age. The concomitant medication taken by the patient was not reported. The patient's risk factor included tobacco abuse. On an unspecified date, the patient was administered with FLUVIRIN (dose, route of administration, anatomical location, batch number, expiry date: not reported) for an unknown indication. On an unspecified date, after administering the FLUVIRIN vaccine the patient developed allergy. The outcome of the event drug allergy was not reported. Reporter's comment: The reporter considered this report as non-serious and the causality of the event drug allergy was related to the FLUVIRIN vaccine.
Began experiencing chills on morning of 12/4/2013. Couldn't sleep the night of 12/4/2013 due to feeling cold. 12/5/2013 woke with "chesty" cough and loss of my voice. Fatigue, "all I did was sleep." Also had body aches all over, joint pain and headache. By 12/8/2013 "I began to feel better."
After the vaccine was given it was discovered the vaccine was expired past the recommended 12 hour period, at most 31 hours after puncture the dose was given. No adverse reaction was reported and the manufacturer was contacted regarding whether the patient needs to be re-dosed to complete the vaccine series
Small rash (US quarter sized) at injection site observed approximately 8 days post-injection (April 1st).  Rash is slightly warm to the touch, slightly itchy, and sore.  Over the next few days, rash grew (softball size on April 5th), still slightly itchy.  Otherwise, patient in good health (no fever, etc.) and able to perform daily activities and exercises.
Breakthrough case: Patient positive for covid on 2/7/22. Received Moderna doses on 2/23/21 and 3/23/21.
Sever body pain (couldn't walk), severe headache, chills (it's100F outside), blurred vision, extreme fatigue
Case number PHEH2044US003612 is an initial spontaneous report from a pharmacist received on 21 FEB 2014. This report refers to a 16-year-old male patient. Past medical history and concomitant medications were not reported. He was vaccinated with FLUCELVAX 2013/2014 (batch number: 006031A) intramuscularly on 19 NOV 2014. No adverse event was reported following the maladministration (inappropriate age at vaccine administration).  Following an internal review on 18 AUG 2014, a significant correction was done for the information received on 21 FEB 2014: The BPI labeling of the event "inappropriate age at vaccine administration" changed from listed to unlisted and added second indication as "drug used in unapproved population".
I developed constant ringing in my left year about 8 weeks after receiving the second shot of the Pfizer/ BioNTech COVID-19 vaccine. I also developed ringing in the right ear that comes and goes, but the ringing on the left ear is constant. This ringing in the ear was preceded by severe vertigo in the morning when I woke up, I could not get out of bed for about 20 min,, it felt like my room was spinning. Once the vertigo subsided, the ringing in the ears started.
sore arm, headache,fuzzy head,  neck pain, body aches, insomnia, tiredness, and  just not feeling well
24JUL PM had OPV; 30JUL 3AM woke up w/t101, irritable eve a/; APAP dec fever; This AM pale, irritable, 1030AM fever, ?difficulty swallowing, ? congestion;
Developed firmness & tenderness at site of injection (Left Deltoid) within a day of vaccination. Has been sore L arm with working and developed axillary lymph 5 or 6 days post vaccination. No systemic symptoms. No treatment prior to report 9/13/05.
Low blood pressure; Fever; Chills; Exhaustion; This spontaneous case was reported by a consumer and describes the occurrence of HYPOTENSION (Low blood pressure), PYREXIA (Fever), CHILLS (Chills) and FATIGUE (Exhaustion) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced HYPOTENSION (Low blood pressure), PYREXIA (Fever), CHILLS (Chills) and FATIGUE (Exhaustion). At the time of the report, HYPOTENSION (Low blood pressure), PYREXIA (Fever), CHILLS (Chills) and FATIGUE (Exhaustion) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. Treatment information was not provided.
pt rcvd vax; pt devel red raised rash on trunk & extremities & face, as well as hives & itching; dermatologist conducted a biopsy of rash & determined pt exp was due to nizatidine;
Initial nurse report received on 30 Dec 2009: This patient younger than 4 month was vaccinated by FLUVIRIN (batch 102141P1) 0.25 ml intramuscular into the thigh on an unknown date. The patient did not experience any other adverse effect.
Left foot became swollen  the day after first dose then continued to swell with numbness in both feet then by the 5th day my right foot became extremely swollen and i went to medical center. A rash formed I also on my ankle area . I took pictures if needed. Spent 2 night in observation at hospital.  Still have numbness and raised skin on my  right toe.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. During 2015, the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. During 2016, the patient was treated by a physician for a vesicular outbreak, which was diagnosed as herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX, vaccine, and/or despite receiving ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
This spontaneous report was received from a pharmacist concerning a patient of unknown gender and age. On 10-JUN-2013 the patient was vaccinated with an expired dose of M-M-R II (HSA) (Lot # 0705AA, Expiration date 11-MAY-2013) (route not provided). No adverse effects were reported. Additional information has been requested.
Patient got the shot and was advised to wait for 15 minutes to monitor side effects.  Five minutes after the shot, patient started to feel weakness on legs, hyperventilation and fall down to the floor.  Paramedic was contacted and patient was helped to lye down to the floor and to breath in the paper bag.  Five minutes later, paramedic came and checking the vital signs.  Patient was monitoring for 10 more minutes and was asked if she was ok to stand up and walk home.  Paramedic left and the patient was helped by her boyfriend to go home.
Case number PHEH2013US023975 is an initial spontaneous report from the pharmacist received on 13 Nov 2013. This report refers to a 62-year-old female patient. She was vaccinated with Flu shot (manufacturer and batch number: not reported, so conservatively coded as Seasonal Influenza vaccine INN on an unknown date. On 13 Nov 2013, one week after the Flu shot the patient accidentally received FLUVIRIN, (batch number: 1308701). No adverse event reported following this medication error.
Lump in right arm 2 months after receiving vax #5. Tingling in right thumb, and in right toe.
Expired vaccine stored and then administered; On 28 Apr 2022, 1 Patient received expired vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (On 28 Apr 2022, 1 Patient received expired vaccine) and PRODUCT STORAGE ERROR (Expired vaccine stored and then administered) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 28-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (On 28 Apr 2022, 1 Patient received expired vaccine). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Expired vaccine stored and then administered). At the time of the report, EXPIRED PRODUCT ADMINISTERED (On 28 Apr 2022, 1 Patient received expired vaccine) and PRODUCT STORAGE ERROR (Expired vaccine stored and then administered) outcome was unknown. Not Provided      For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Reporter reported that the vials were continuously stored in stable freezer environment. Only stored in fridge on date of administration for thaw period.  Concomitant drugs were not reported.  Treatment details were not given.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Mar-2021 at 9:44 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 30-Mar-2021 at 9:44 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 66.66 for dose administered on 02-Mar-2021 and 66.74 for dose administered on 30-Mar-2021  No concomitant medications were reported. Batch number 019B21A underwent temperature excursion on 30-Mar-2021 with temperature 33 degrees Fahrenheit at 09:00 AM. This vial was moved to fridge on 23-Mar-2021 and beyond use date for the vial was reported as 22-Apr-2021. Product moved to clinic on 30-Mar-2021. Batch number 014M20A underwent temperature excursion on 02-Mar-2021 with temperature 27 degrees Fahrenheit at 9 AM, 29 degrees Fahrenheit at 10 AM, 32 degrees Fahrenheit at 11 AM, 33 degrees Fahrenheit at 12 PM, 35 degrees Fahrenheit at 2 PM and 36 degrees Fahrenheit at 3PM. This vial was moved to fridge on 24-Feb-2021 and beyond use date for the vial was reported as 26-Mar-2021. Product moved to clinic on 02-Mar-2021.Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour.  No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
Pt recv vax on 1/29/99; on same day pt exp unresponsiveness, pale, limp; tx= antibiotics & IV fluids
Closed left nostril, weakness of muscles on left side of face, inability to fully blink with left eye, inability to close left side of mouth tightly, etc.
Patient was 8 weeks pregnant at time of administration; No adverse effects reported; This spontaneous prospective pregnancy report has been received from a medical assistant referring to a female patient of unknown age. The patient's concomitant medication, pertinent medical history, drug reactions or allergies were not reported.  On 24-SEP-2019, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (lot number: S006048, expiration date: 27-FEB-2021; strength and route were not reported) and varicella virus vaccine live (oka/merck)(VARIVAX) (lot number: S006018, expiration date: 27-FEB-2021; strength and route were not reported), both for prophylaxis. The patient was 8 weeks pregnant at time of administration. No adverse effects reported. The patient's last menstrual period (LMP) was 30-JUL-2019 and the estimated date of delivery (EDD) was 05-MAY-2020. The pregnancy outcome was pending. The outcome of the events was unknown.
On 8/7/00, the pt was admitted to the hospital with congestive heart failure and polymyositis. The pt is still currently in the hospital. Followup information received 3/6/01 reports pt not hospitalized with CHF but with dermatomyonitis, respiratory failure, acute renal failure and other conditions.
administered expired vaccine to patients, after the manufacture date of expiration; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered expired vaccine to patients, after the manufacture date of expiration) in a 61-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 12-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered expired vaccine to patients, after the manufacture date of expiration). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered expired vaccine to patients, after the manufacture date of expiration) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment medication was not reported. Number of doses administered was 173 doses. The vial did not undergo any temperature excursions.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Follow up received contains Non-significant information.
My arms and hands became numb and paralyzed. My face become tingly and paralyzed . I went to the ER
pt had 1st shingrix shot on weds 5/29/19,  local arm soreness began shortly after as expected, then fri am 05/31/19  pt began to develop widespread, red "chicken-pox" like rash, just like chicken pox on trunk arms and legs. this rash subsided with bendaryl and calamine lotion  but was slightly unsightly and uncomfortable. pt reports having experienced chick posx two times as a child. this vaccine gave patient an episode of chicken pox.